A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

NCT07299422 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

248

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: SHR-2173 Injection
DRUG: SHR-2173 Injection Placebo

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd